Journal article · 2005 · Open access

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy

Zubeir Nurgat, Wendy L. Craig, Neil C Campbell, J D Bissett, J Cassidy, Marianne C. Nicolson

British Journal of Cancer, 92(6), 1001–1005 · Published 1 March 2005 · DOI 10.1038/sj.bjc.6602423

Open PDFView at the publisherCite this paper

In brief

“Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy” is a 2005 journal article by Zubeir Nurgat and 5 co-authors, published in British Journal of Cancer. OpenAlex counts 160 citations as of 22 November 2026, which puts it in the top 8% of works published in 2005 by citations. It is open access under a CC BY-NC-SA licence: the full text is free to read at British Journal of Cancer.

Citations
160
Most cited in
2021 (14)
Field-weighted impact
7.37
References
29
Authors
6

Abstract

Successful advances in the treatment of advanced malignant diseases rely on recruitment of patients into clinical trials of novel agents. However, there is a genuine concern for the welfare of individual patients. The aim of this study was to examine motives of patients entering early clinical trials of novel cancer therapies. Questionnaire survey with both open- and close-ended questions. The patients were surveyed after they had given informed consent and before or during the first cycle of treatment. In all, 38 phase I/II trial patients participated and completed the survey. Obtaining possible health benefit was listed by 89% as being a 'very important' factor in their decision to participate, with only 17% giving reasons of helping future cancer patients and treatment. Other items cited as a 'very important' motivating factor were 'trust in the doctor' (66%), 'being treated by the latest treatment available' (66%), 'better standard of care and closer follow-up' (61%), and 'closer monitoring of patients in trials' (58%). Only 47% patients indicated that someone had explained to them about any 'reasonable' alternatives to the trial. In total, 71% strongly agreed that 'surviving for as long time as possible was the most important thing (for them)'. Nearly all (97%) indicated that they knew the purpose of the trial and had enough time to consider participation in the trial (100%). In this survey, most patients entering phase I and II clinical trials felt they understood the purpose of the research and had given truly informed consent. Despite this, most patients participated in the hope of therapeutic benefit, although this is known to be a rare outcome in this patient subset. Trialists should be aware, and take account of the expectations that participants place in trial drugs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nurgat, Z., Craig, W. L., Campbell, N. C., Bissett, J. D., Cassidy, J., & Nicolson, M. C. (2005). Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. British Journal of Cancer, 92(6), 1001–1005. https://doi.org/10.1038/sj.bjc.6602423

MLA 9

Nurgat, Zubeir, et al. “Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.” British Journal of Cancer, vol. 92, no. 6, 2005, pp. 1001–1005. https://doi.org/10.1038/sj.bjc.6602423.

Chicago

Nurgat, Zubeir, Wendy L. Craig, Neil C Campbell, J D Bissett, J Cassidy, and Marianne C. Nicolson. 2005. “Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.” British Journal of Cancer 92 (6): 1001–1005. https://doi.org/10.1038/sj.bjc.6602423.

Harvard

Nurgat, Z. et al. (2005) ‘Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy’, British Journal of Cancer, 92(6), pp. 1001–1005. doi:10.1038/sj.bjc.6602423.

IEEE

Z. Nurgat, W. L. Craig, N. C. Campbell, J. D. Bissett, J. Cassidy, and M. C. Nicolson, “Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy,” British Journal of Cancer, vol. 92, no. 6, pp. 1001–1005, 2005, doi: 10.1038/sj.bjc.6602423.

BibTeX

@article{nurgat2005patient,
  title     = {{Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy}},
  author    = {Nurgat, Zubeir and Craig, Wendy L. and Campbell, Neil C and Bissett, J D and Cassidy, J and Nicolson, Marianne C.},
  journal   = {British Journal of Cancer},
  year      = {2005},
  volume    = {92},
  number    = {6},
  pages     = {1001--1005},
  doi       = {10.1038/sj.bjc.6602423},
  url       = {https://doi.org/10.1038/sj.bjc.6602423}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201799
201844
201944
202055
20211414
202255
202344
202477
202522
202688

Its field-weighted citation impact is 7.37: it has been cited 7.37 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research

  • clinical trial participation
  • patient motivation
  • cancer chemotherapy
  • informed consent
  • trust in physicians
  • patient decision-making
  • advanced cancer

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Nurgat, Z., Craig, W. L., Campbell, N. C., Bissett, J. D., Cassidy, J., & Nicolson, M. C. (2005). Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. British Journal of Cancer, 92(6), 1001–1005. https://doi.org/10.1038/sj.bjc.6602423

How many times has this paper been cited?

160 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at British Journal of Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Zubeir Nurgat, Wendy L. Craig, Neil C Campbell, J D Bissett, J Cassidy, Marianne C. Nicolson.

What is the DOI of this paper?

10.1038/sj.bjc.6602423, permanently at https://doi.org/10.1038/sj.bjc.6602423. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.